• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Rudi Dierckx highlights the key industry challenges and opportunities in nuclear medicine.

• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Dierckx explores the research that is opening new perspectives across all therapeutic areas.

• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Rudi Dierckx navigates through the evolving landscape of nuclear medicine, from the significant advancements to the growing interest of pharmaceutical industry.

V. Bonvin^{a ,b, *}, F. Bochud^b, J. Damet ^b,d , C. Theis^a, H. Vincke^a,c, R. Geyer^a,b
aEuropean Council for Nuclear Research (CERN), Esplanade des Particules, CH-1211, Meyrin, Switzerland
^bInstitute for Radiation Physics, Lausanne University Hospital, Rue du Grand-Pr´ e, CH-1007, Lausanne, Switzerland
^cUniversity of Technology, Rechbauerstraße 12, 8010, Graz, Austria
^dUniversity of Otago, 2 Riccarton Ave, Christchurch, New Zealand   

C. Gameiro¹, V. H. Alves², A. Abrunhosa³, F. Alves², D. Goblet¹, B. Nactergal¹, A. Uhlending³, V. Hugenberg³, T. Ortgies³, G. Hoeger³, J. Manrique-Arias⁴, R. Freifelder⁵, K. Hye-Yeong⁵, M. Bhuiyan⁵,  A. Kucharski^5 
1IBA, Louvain-La-Neuve, BELGIUM,
²Institute for Nuclear Sciences Applied in Health (ICNAS), Coimbra, PORTUGAL,
³Department of Radiology, Nuclear medicine and Molecular Imaging, Bad Oeynhausen, GERMANY,
⁴Cyclotron Department, Doctors Hospital, Monterrey, MEXICO,
⁵Department of Radiology, University of Chicago, Chicago, IL, US.

IBA RadioPharma Solutions & IBA Customer Service, Louvain-la-Neuve, Belgium
Cyclotron Research Center, University of Liège, Belgium- link 

Nicholas P. van der Meulen^1,2,*, Roger Hasler², Chiara Favaretto ², Zeynep Talip ², Pascal V. Grundler ², Christoph A. Umbricht ², Cristina Müller ², Tommaso S. Carzaniga ³  and Saverio Braccini ³, Gaia Dellepiane ^3
1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
²Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland; rogerhasler26@gmail.com (R.H.); zeynep.talip@psi.ch (Z.T.); pascal.grundler@psi.ch (P.V.G.); chiara.favaretto@psi.ch (C.F.); christoph.umbricht@gmail.com (C.A.U.); Cristina.mueller@psi.ch (C.M.) 
³Albert Einstein Center for Fundamental Physics, Laboratory of High Energy Physics, University of Bern, 3012 Bern, Switzerland; gaia.dellepiane@lhep.unibe.ch (G.D.); tommaso.carzaniga@lhep.unibe.ch (T.S.C.); saverio.braccini@lhep.unibe.ch (S.B.) 
^*Correspondence: nick.vandermeulen@psi.ch

Christopher Marshall , Adam Dabkowski , Matthew Talboys , Sophie Wiltshire , Ken Buckley , Stuart McDiarmid , Victoire Hanemaayer , Stefan Zeisler , Paul Schaffer , Fabienne Devillet and Delphine Blampain

Objective(s): The aim of this research was the development of ¹¹¹In‐labeled porphyrins as possible radiopharmaceuticals for the imaging of tumors.            

Shaghayegh Sadeghi, Mohammad Mirzaei, Mohammad Rahimi, Amir R. Jalilian

Samy Bertrand, Jean-Michel Geets, Cristiana Gameiro, Benoit Nactergal, Jeremy Brison
IBA SA,Louvain-la-Neuve, Belgium